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| THE BIOLOGY OF GROUP INNATE LYMPHOID CELLS
In mice, ILC2s were originally identified as a type 2 cytokine expressing cell subset, which could not be classified by conventional lineage markers for T cells, B cells, NK cells, macrophages, dendritic cells, neutrophils, eosinophils, basophils or mast cells, but expressed the common leucocyte antigen (LCA) CD45 and their morphology resembled those of typical lymphocytes. 1, 2, 12 Early studies identified the markers IL-17 receptor B, in combination with IL-17RA forming the IL-25
receptor, the IL-33 receptor (T1/ST2) with varying expression of the stem cell factor c-kit (CD117). 1,2 These innate lymphoid-like cells were given various names including nuocytes, 1 innate helper type 2 cells (Ih2) 2 or natural helper cells. 13 They were enriched in mesentery 13 and have been shown to express the common gamma chain (γ c , CD132)-associated receptors CD25 (IL-2Rα) and CD127 (IL-7Rα). IL-7 be has been shown to play an essential role in the development and survival of ILC2s and ILC3s. [14] [15] [16] Human ILC2s were initially described by Mjosberg et al. 17 as being similar to murine ILC2s in lacking the expression of classical lineage defining markers, but being positive for the leucocyte marker CD45 and the IL-7Rα (CD127). In addition, human ILC2s express the "chemokine receptor homologous molecule expressed on TH2 cells" (CRTH2=CD294), 17 a marker well characterized for its expression on human CD4+ T H 2 cells, 18 the NK cell receptor NKR-P1A (CD161) 17 and ST2 19 (a member of the IL-1 family receptors), which is part of the IL-33 receptor complex. 20 A combination of these markers is frequently used for identifying human ILC2s as Lin-CD45+CD127+CRTH 2+CD161+(ST2+) 11, 17, [21] [22] [23] as we depict in the flow chart for analysing human ILC2 by flow cytometry (Figure 1 ).
Apart from the IL-7Rα, ILC2s express the IL-2Rα (CD25) 17 was shown in mice, and basophil-derived IL-4 can positively control ILC2s. 35 As IL-4 is secreted by ILC2s, IL-4 could potentially act as an F I G U R E 1 Identification of human ILC2s by flow cytometry as conducted in our studies. PBMCs were isolated from human peripheral blood and analysed by multifluorochrome-based flow cytometry. PBMCs were gated on leucocytes (A), single cells (B) and live cells using a viability dye (C). Live single cells were gated on lineage negative (CD3, CD14, CD16, CD19, CD20, CD56, CD123, CD11c, αβTCR γδTCR), CD45+ (D), CD127+ (E) and CD161+CRTH2+ cells (F), which finally leads to the identification of lin-CD45+CD127+CRTH2+CD161+ ILC2s autocrine feedback mechanism for activation of ILC2s. However, the exact role of IL-4 in controlling activation of human ILC2s is currently unknown. ILC2s are also the main source of IL-9, another common γ chain (γ c ) cytokine, 36, 37 with expression of IL-9 receptor being essential for ILC2 activation, survival of activated ILC2s and finally for efficient helminth worm expulsion in mouse experimental models.
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IL-9 released by lung resident ILC2s plays a central role in the epithelial response to murine N. brasiliensis infection by inducing IL-5 and IL-13 production. 38 Gene expression analyses indicated that the IL-9
receptor is expressed on murine ILC2s, and in humans, expression of this receptor has been shown on blood and lung ILC2s. 21 The CRTH2 Murine ILC2s isolated from lymph nodes and the spleen, and to a less extent, ILC2s from the peritoneal or broncho-alveolar lavage, express major histocompatibility complex class-II (MHC-II) molecules.
They also express the co-stimulatory molecules CD80 and CD86. T-cell response including generation of T H 2 memory CD4+ T cells as outlined and described in Figure 2 . 
| Common γ c cytokine receptors
Common gamma chain (γ c ) (CD132) cytokine receptors play a central role in the development, homoeostasis and function of several immune cell lineages and are indispensable for the immune system itself.
Therefore, it is not surprising that common γ c cytokines and the corresponding receptors are also essential for the development of ILC2s.
The IL-7Rα chain, forming a heterodimer with the common γ c (also known as common IL-2 receptor gamma chain), was one of the first surface receptors identified as marker for ILCs, and the development of ILC2s was depending on the common γ c and IL-7. 13 The IL-2Rα is also a marker human ILC2s and provides an important co-stimulatory signal for the activation of ILC2s.
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Using a reporter mouse strain, ILC2s, rather than CD4+ T cells,
were also identified as main source of IL-9 in a model of airway inflammation. 37 More importantly, IL-9 acts as feedback signal enhancing the cytokine production by ILC2s. The importance of IL-9 as a feedback signal was subsequently confirmed in experimental infection with N. brasiliensis, in which IL-9 receptor expressing ILC2 is important for restoring tissue damage caused by the lung stage of N. brasiliensis.
36,38
Hence, common γ c receptors play a pivotal in the development, maintenance and activation of ILC2s.
In T cells, common γ c signalling is mainly mediated by three 
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While the importance of common γ c cytokine receptors for ILC2s is well described for mice, the precise signalling pathways controlling the development and function of human ILC2s remain to be investigated.
| LOCATION OF ILC2S AND THE IMPLICATION FOR HUMAN HELMINTH INFECTIONS
ILC2s have been identified in various tissues. Using reporter mice in experimental models of N. brasiliensis infection, ILC2s were identified in the spleen, liver, mesenteric lymph nodes, the intestine, fatassociated lymphoid clusters 1,2,13 and skin. 62 In humans, ILC2s have been described in nasal polyps, tonsils, gastrointestinal tract, peripheral blood 17, 25 and the lung. 9,17 ILC2 are also described in human skin 46, 63 with their migration to the skin being associated with PGD2, the ligand for CRTH2, 63 and the skin-homing marker cutaneous lymphocyte antigen. 64 Overall, mucosa-associated tissues of the lung, intestine and skin are now widely accepted as the most important locations for ILC2s. ILCs derive from a common lymphoid precursor in bone marrow 74 expressing the integrin α 4 β 7 , mediating migration to endothelial venues and mucosal tissues, and chemokine receptor CXCR6 mediating migration to the intestine. 75 Additionally, a lineage-specific precursor has been identified for ILC2s. 24, 47 However, it has been suggested that ILC2s proliferate within tissues and are rarely replenished from the bone marrow. 45 More committed progenitors were also identified in secondary lymphoid organs. 76 Therefore, the contribution of circulating ILC2s
from peripheral blood to tissue-resident ILC2 pool needs to be studied 81 The frequency of c-
| ILC2S IN HUMAN HELMINTH INFECTION-WHAT WE DO "NOT" KNOW

kit+ ILCs and IL-13 producing cells among c-kit+ ILCs was increased in filarial infected individuals. The proportion of c-kit ILCs correlated with IL-17-producing CD4+ T cells and ex vivo stimulation of enriched ILCs
released IL-5 and IL-13, but also IL-10, IL-17 and IFNγ. 81 In a different study, we evaluated ILC2s in context of natural infection with S. haematobium in Zimbabwean children. 11 Schistosomeinfected children aged 6-13 years (as diagnosed by parasite egg excretion) had a significantly lower frequency of ILC2s in the peripheral blood compared to same-age schistosome-uninfected children ( Figure 3A ). In contrast, older infected children (aged 14-18 years) had comparable levels of ILC2s to uninfected children. 11 Proportions of ILC2s recovered following curative antihelminthic treatment ( Figure 3B ). Of note is the difference in these age groups; children are exposed to schistosome infection very young and therefore acquire infection at a young age. 82 By the time they reach adolescence, they will have experienced several re-infection events. Thus, it is possible that the ILC2 dynamics are reflecting differences occurring upon first vs repeated infection events. Older egg-positive children had levels of ILC2s comparable to same-age egg-negative children. These older egg-positive children show a schistosome-specific antibody profile, which indicates a history of previous infection and also associated with the development of protective immunity, beginning to reduce re-infection levels. [83] [84] [85] This finding may indicate that ILC2s play a ). Severe forms of pathology are associated with T H 1/T H 17, whereas mild pathology is associated with a combination of regulatory and T H 2 response. However, the type 2 cytokine IL-13 also contributes to hepatic fibrosis. 106 In mouse models, it has been shown that ILC2s are a likely source for IL-13 in hepatic fibrosis. 107 Hepatic IL-33 triggered the expansion and activation of liver-resident ILC2s, which produced IL-13 and mediated fibrosis. 107, 108 In human intestinal schistosomiasis, the majority of patients develop a less severe form of the disease, but about 5%-10% suffer from hepatosplenic schistosomiasis with progressive fibrosis. 109 To what extent, hepatic ILC2s contribute to the development of severe forms of schistosomiasis remains to be investigated. Furthermore, the impact of environmental enteropathy, which affects gut permeability, exacerbated by helminth infections has yet to be investigated. ; that is, the host needs to experience a threshold of antigens to mount an effective immune response and that these antigens become available following worm death. We and others have also demonstrated the requirement of the ratio of regulatory vs effector cellular immune to favour effector responses for expression of resistance. 118 However, the precise mechanism of the induction of a Apart from the direct use of cytokines in immunotherapies, molecules crucial for the downstream signalling induced by these cytokine could be targeted. Interestingly, the effects by IL-7 in the study on chronic viral infections were partially mediated by repression of SOCS3. 144 Hence, targeting the JAK/STAT or the MAPK/Erk pathway including SOCS inhibitors may have the potential to increase ILC2 activation, but also T H 2 responses in general. 53, 146 The main trigger of the ILC2 activity are the alarmins IL-25, IL-33
| MODULATING ILC2 RESPONSES
and TSLP, but their potential as activators in immunotherapy has not been investigated in detail. However, blocking alarmins has been considered for treating allergic diseases, 147-149 but has not really gone beyond experimental testing with only initial studies in human. 150 
ILC2
targeting alarmins could be also used in combination with common γ c cytokines. Overall, specific modulation of ILC2 activity to improve vaccine or I&T-induced protective immune responses is an exciting idea.
Precise treatment strategies need to be carefully approved to avoid induction of regulatory T cells or to avoid the induction of allergic immune responses. Before attempting ILC2 targeting strategies to build up protective immune responses, much more work needs to be done on dissecting mechanisms and signalling pathways in ILC2s. 
| CONCLUSIONS
